Sanofi Says Genzyme Integration Is On Track, But Fabrazyme Production Won't Meet Goals

Full production of the rare disease drug is pushed back a quarter, but analysts warm to Sanofi's full-year guidance and ability to meet overall goals for R&D and Genzyme integration.